Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00946712 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT00946712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00946712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Terminated
Start date
July 15, 2009
Completion date
February 8, 2022
Enrollment
1,333 (actual)
Sites
798

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent large cell lung carcinoma, recurrent lung adenocarcinoma, recurrent squamous cell lung carcinoma, stage iv large cell lung carcinoma, stage iv lung adenocarcinoma, stage iv squamous cell lung carcinoma